Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P51810

UPID:
GP143_HUMAN

ALTERNATIVE NAMES:
Ocular albinism type 1 protein

ALTERNATIVE UPACC:
P51810; Q6NTI7

BACKGROUND:
The G-protein coupled receptor 143, also known as the ocular albinism type 1 protein, is essential for melanosome function in melanocytic cells. By binding to L-DOPA, it stimulates Ca(2+) influx, increases secretion of neurotrophic factor SERPINF1, and relocalizes beta arrestin, indicating its broad role in cellular signaling and melanosome biogenesis.

THERAPEUTIC SIGNIFICANCE:
Linked to Albinism ocular 1 and congenital Nystagmus 6, GPR143's involvement in these diseases underscores the importance of its study for developing targeted therapies. Exploring GPR143's functions and pathways offers a promising avenue for creating interventions that could alleviate the visual impairments associated with these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.